Novozymes A/S
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ester Baiget
- Full Time Employees
- 11,641
- Sector
- Basic Materials
- Industry
- Chemicals - Specialty
- Address
- Krogshoejvej 36 Lyngby ND Denmark 2880
- IPO Date
- Jan 20, 2010
- CIK
- 0001131345
- Website
- novozymes.com
- Similar Companies
- Business
- Novozymes A/S, a biotechnology company specializing in the research, development, and production of industrial enzymes, microorganisms, proteins, and biopharmaceutical ingredients, operates across diverse sectors including household care, food and beverages, agriculture, bioenergy, animal nutrition, pharmaceuticals, biopharma, pulp and paper, textiles, leather, and wastewater treatment; its core offerings encompass over 700 enzyme types such as lipases, proteases, oxidoreductases, and carbohydrases, alongside nutraceutical ingredients including natural botanicals, vitamins, drain openers, hard surface cleaners, medical cleaning solutions, septic tank treatments, ware washing products, professional laundry services, and industrial hygiene solutions. Founded in 2000 as a spin-off from Novo Nordisk and headquartered in Bagsværd, Denmark, the company serves more than 130 markets worldwide with operations in Europe, North America, Latin America, Asia-Pacific, China, India, Brazil, Argentina, the United Kingdom, the United States, and Canada, targeting industrial, agricultural, consumer, and health-related customers through its business segments of Food & Health Biosolutions (food, beverages, human health) and Planetary Health Biosolutions (household care, agriculture, energy, and technical processing). In a transformative development, Novozymes merged with Chr. Hansen in January 2024 to form Novonesis A/S, creating a global biosolutions leader with combined annual revenue exceeding €3.7 billion, approximately 10,000 employees, and enhanced capabilities in enzymes, microbial solutions, and fermented proteins; this strategic combination, announced in December 2022 and cleared by regulators, unlocks synergies in innovation, commercial scale, and sustainability-focused growth, including 18 new solution launches in 2023 and ongoing investments in RDI for industrial enzymes and microorganisms. As Novonesis, the entity advances its GROW strategy with 2030 targets of 6-9% organic sales CAGR, ~39% adjusted EBITDA margin, and ~16% adjusted ROIC excluding goodwill, alongside a €100 million share buyback program for 2025 and elevated capex for innovation, ERP systems, sustainability, and global capacity expansion in areas like biopharma processing aids, future fuels, chemicals, and specialized nutrition proteins.
FUL or NVZMY: Which Is the Better Value Stock Right Now?
FUL or NVZMY: Which Is the Better Value Stock Right Now?
FUL vs. NVZMY: Which Stock Should Value Investors Buy Now?
FUL or NVZMY: Which Is the Better Value Stock Right Now?
Analyzing Novozymes A/S (OTCMKTS:NVZMY) & Orion (NYSE:OEC)
Novozymes A/S (NVZMY) Q4 2025 Earnings Call Transcript
NVZMY vs. HWKN: Which Stock Is the Better Value Option?
Novozymes A/S (OTCMKTS:NVZMY) Short Interest Update
KROS or NVZMY: Which Is the Better Value Stock Right Now?
Novozymes A/S (NVZMY) Q3 2025 Earnings Call Transcript
KMDA vs. NVZMY: Which Stock Is the Better Value Option?
Novonesis A/S (NVZMF) Q2 2025 Earnings Call Transcript
Novozymes (NVZMY) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Novonesis: Industry Leader With Defensive Characteristics And Solid Growth
Is Novozymes (NVZMY) Stock Outpacing Its Basic Materials Peers This Year?
Best Income Stocks to Buy for May 14th
New Strong Buy Stocks for May 14th
Novonesis A/S (NVZMF) Q1 2025 Earnings Call Transcript
All You Need to Know About Novozymes (NVZMY) Rating Upgrade to Strong Buy
AXTA or NVZMY: Which Is the Better Value Stock Right Now?